高级检索
当前位置: 首页 > 详情页

Hirudo Lyophilized Powder Ameliorates Renal Injury in Diabetic Rats by Suppressing Oxidative Stress and Inflammation

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Univ Chinese Med, Shijiazhuang 050091, Hebei, Peoples R China [2]Hebei Univ Tradit Chinese Med, Affiliated Hosp, Shijiazhuang 050011, Hebei, Peoples R China
出处:
ISSN:

摘要:
As diabetic nephropathy (DN) is one of the most common and destructive microvascular complications of diabetes mellitus, the goal of this study, therefore, was to investigate the renal protective effect and latent mechanisms of Hirudo lyophilized powder on diabetic rats. In this study, all rats were randomly assigned into the control group and diabetic group. The rats of diabetic group were injected with low-dose STZ (35 mg/kg) intraperitoneal plus high-fat diet to induce diabetes. Then, the successful diabetic model rats were weighed and randomly assigned into four groups: (1) diabetic model group (DM group); (2) Hirudo lyophilized powder 0.3 g/kg treatment group (SL group); (3) Hirudo lyophilized powder 0.6 g/kg treatment group (SM group); (4) Hirudo lyophilized powder 1.2 g/kg treatment group (SH group). Their fasting blood glucoses (FBG) were measured every 4 weeks. After treatment with Hirudo lyophilized powder at a corresponding dose once a day for 16 weeks, their metabolic and biochemical as well as oxidative stress parameters were tested, and the kidney weight (KW)/body weight (BW) was calculated. The renal tissues were used for histological, mRNA, and protein expression analysis. The results showed that Hirudo lyophilized powder could protect against the structural damages and functional changes of diabetic renal tissue by inhibiting oxidative stress, inflammation, and fibrosis. Furthermore, it was found in the further research that inhibiting the NOX4 expression and JAK2/STAT1/STAT3 pathway activation might be the underlying mechanisms. Collectively, Hirudo lyophilized powder might be a promising therapeutic agent for the treatment of DN.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 全科医学与补充医学
最新[2025]版:
JCR分区:
出版当年[2021]版:
Q3 INTEGRATIVE & COMPLEMENTARY MEDICINE
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版]

第一作者:
第一作者机构: [1]Hebei Univ Chinese Med, Shijiazhuang 050091, Hebei, Peoples R China
通讯作者:
通讯机构: [1]Hebei Univ Chinese Med, Shijiazhuang 050091, Hebei, Peoples R China [2]Hebei Univ Tradit Chinese Med, Affiliated Hosp, Shijiazhuang 050011, Hebei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15679 今日访问量:0 总访问量:1035 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号